Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in patients with decompensated cirrhosis

Conference name: 2nd International conference on pathology

Short name: Pathology 2019

Venue : Paris,France | July 5-6,2019

URL: https://bit.ly/2GS09CI

The efficacy of bi-monthly hepatic arterial infusion chemotherapy (B-HAIC) was not inferior to that of Sorafenib chemotherapy for the treatment of advanced hepatocellular carcinoma (aHCC) in patients with compensated cirrhosis. In this study, we demonstrate the efficacy of B-HAIC in patients with decompensated cirrhosis.

The efficacy rate and the disease control rate in the Child–Pugh B group (21% and 71%, respectively) were not significantly impaired compared with the rates in the Child–Pugh A group (38% and 67%, respectively). The median survival time and the survival rate at 12 months of patients in the Child–Pugh B group were 422 days and 58.3%, respectively, whereas those in the Child–Pugh A group were 567 days and 70.8%, respectively. Importantly, the hepatic functional reserve of patients in each group did not worsen during the treatment period. Furthermore, the occurrence rate of serious adverse events leading to discontinuation of anti-tumour treatment in both groups was quite limited despite the preserved hepatic functional reserve in these patients.

To know more about Pathology and its Applications do attend International Conference on Pathology 2019 http://pathology.alliedacademies.com/

Contact
KRISTIE NOVA
Program Director | PATHOLOGY 2019
Phone: (44) 20 3769 1755
Email: pathology(at)alliedannualsummit(dot)com